CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity.
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞在自发性免疫和治疗性免疫治疗过程中往往不存在于人类癌症组织中,即使存在功能性的T细胞招募趋化因子系统,这表明存在损害浸润的T细胞排斥机制。利用全基因组体外筛选平台,我们确定了磷脂酶A2第10组(PLA2G10)蛋白在T细胞排斥中的作用。PLA2G10上调在人类癌症中广泛存在,并与肿瘤组织中T细胞浸润不良相关。在免疫原性小鼠肿瘤中过表达PLA2G10可将T细胞排除在浸润之外,导致对抗PD-1免疫治疗产生耐药性。PLA2G10可将磷脂水解为小脂质代谢物,从而抑制趋化因子介导的T细胞运动。消除PLA2G10的酶活性可增强T细胞浸润,并使过表达PLA2G10的肿瘤对免疫治疗敏感。我们的研究揭示了PLA2G10在T细胞排斥肿瘤中的作用,并提出了癌症免疫治疗的潜在靶点。
T cells are often absent from human cancer tissues during both spontaneously induced immunity and therapeutic immunotherapy, even in the presence of a functional T cell-recruiting chemokine system, suggesting the existence of T cell exclusion mechanisms that impair infiltration. Using a genome-wide in vitro screening platform, we identified a role for phospholipase A2 group 10 (PLA2G10) protein in T cell exclusion.
PLA2G10 up-regulation is widespread in human cancers and is associated with poor T cell infiltration in tumor tissues. PLA2G10 overexpression in immunogenic mouse tumors excluded T cells from infiltration, resulting in resistance to anti-PD-1 immunotherapy. PLA2G10 can hydrolyze phospholipids into small lipid metabolites, thus inhibiting chemokine-mediated T cell mobility. Ablation of PLA2G10's enzymatic activity enhanced T cell infiltration and sensitized PLA2G10-overexpressing tumors to immunotherapies.
Our study implicates a role for PLA2G10 in T cell exclusion from tumors and suggests a potential target for cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。